DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.
Kizhakeyil A, Zaini NBM, Poh ZS, Wong BHS, Loh X, Ng AS, Low ZS, Prasannan P, Gong C, Tan MGK, Nagarajan C, Huang D, Lu PW, Lim JQ, Barrans S, Ong CK, Lim ST, Chng WJ, Follows G, Hodson DJ, Du MQ, Goh YT, Tan SH, Grigoropoulos NF, Verma NK.
Kizhakeyil A, et al. Among authors: wong bhs.
Mol Cancer. 2021 Oct 16;20(1):134. doi: 10.1186/s12943-021-01437-0.
Mol Cancer. 2021.
PMID: 34654425
Free PMC article.
No abstract available.